Physician profile
Mary E Holsinger
NPI 1649604232
$2,471.37
in general payments reported to CMS, 2019-2025
29 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $519 · 2022: $1,016 · 2023: $639 · 2024: $137 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $917 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $917.31 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $651.14 | 2021-2023 | |
| Novo Nordisk INC | $316.56 | 2021-2023 | Wegovy |
| Abbott Laboratories | $282.92 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $186.98 | 2022-2023 | Mounjaro, Trulicity, Jardiance |
| Exact Sciences Corporation | $103.42 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $100.14 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.63 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $82.48 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $76.90 | 2021 | |
| Mylan Specialty L.P. | $57.91 | 2021-2022 | |
| Dynavax Technologies Corporation | $52.08 | 2022-2023 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $50.62 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $48.60 | 2022-2023 | Fasenra, Farxiga |
| Amgen INC. | $48.10 | 2022-2024 | Krystexxa, Prolia, Evenity |
| Horizon Therapeutics Plc | $47.41 | 2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.66 | 2021 | |
| Pfizer INC. | $35.60 | 2023-2025 | |
| Inspire Medical Systems, INC. | $33.50 | 2024-2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $27.55 | 2022-2023 | Quviviq |
| Merck Sharp & Dohme LLC | $19.72 | 2022 | |
| Glaxosmithkline, LLC. | $19.10 | 2023 | Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $16.69 | 2023 | |
| Corium, LLC | $15.87 | 2022 | |
| Medtronic, INC. | $14.57 | 2022 | |
| Currax Pharmaceuticals LLC | $14.43 | 2021 | |
| Edwards Lifesciences Corporation | $13.95 | 2022 | |
| Gilead Sciences, INC. | $13.05 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.93 | 2022 | |
| Clarus Therapeutics INC. | $7.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Holsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.